Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05602220
Other study ID # UP-21-00357
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 11, 2023
Est. completion date November 13, 2023

Study information

Verified date April 2024
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the current study, we will examine how daily paced breathing affects plasma amyloid beta levels and the rate of learning in older adults. Healthy adults aged 50-70 who meet all eligibility criteria will be invited to this study. Participants will be randomly assigned to one of the two conditions: 1) Daily memory and attention training followed by a paced breathing protocol designed to increase relaxation or 2) Daily memory and attention training followed by a paced breathing protocol to increase alertness. Participants will be asked to complete pre and post intervention cognitive testing online, engage in 10 weeks of daily brain training (starting Week 2) and 9 weeks of paced breathing (starting Week 3) at home. They will also be asked to come in for lab visits on Weeks 2, 7 and 12 to provide blood and urine samples to assess amyloid beta levels and to complete magnetic resonance imaging scans to assess perivascular space volume.


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date November 13, 2023
Est. primary completion date November 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 70 Years
Eligibility Inclusion Criteria: - speak English fluently - between the age of 50-70 - healthy adult who weighs at least 110 pounds - non-pregnant and non-menstruating (for at least the past year) - normal or corrected-to-normal vision and hearing - have a home computer with a physical keyboard and have access to reliable internet - have an email account that you check regularly - have a phone that receives text messages - willing to provide a blood sample and a urine sample at three lab visits - willing to devote up to 60 minutes daily to the study for 12 weeks (in addition to lab visits) Exclusion Criteria: - have a disorder that would impede performing the breathing intervention (e.g., abnormal cardiac rhythm, heart disease including coronary artery disease, angina, and arrhythmia, cognitive impairment, dyspnea) - regularly practicing any relaxation, biofeedback, or breathing technique (e.g., meditation) for more than an hour a week - regularly played Lumosity games in the past 6 months - participated in heart rate biofeedback studies in the USC Emotion & Cognition Lab - have any conditions listed below that are not safe for MRI - Claustrophobia - Have worked as a machinist, metal worker, or in any profession or hobby grinding metal? - Have had an injury to the eye involving a metallic object (e.g., metallic slivers, shavings, or foreign body) - Cardiac pacemaker - Implanted cardiac defibrillator - Aneurysm clip or brain clip - Carotid artery vascular clamp - Neurostimulator - Insulin or infusion pump - Spinal fusion stimulator - Cochlear, otologic, ear tubes or ear implant - Prosthesis (eye/orbital, penile, etc.) - Implant held in place by a magnet - Heart valve prosthesis - Artificial limb or joint - Other implants in body or head - Electrodes (on body, head or brain) - Intravascular stents, filters - Shunt (spinal or intraventricular) - Vascular access port or catheters - IUD - Transdermal delivery system or other types of foil patches (e.g., Nitro, Nicotine, Birth control, etc.) that cannot be removed for MRI - Shrapnel, buckshot, or bullets - Tattooed eyeliner or eyebrows - Body piercing(s) that cannot be removed for MRI - Metal fragments (eye, head, ear, skin) - Internal pacing wires - Aortic clips - Metal or wire mesh implants - Wire sutures or surgical staples - Harrington rods (spine) - Bone/joint pin, screw, nail, wire, plate - Wig or toupee that cannot be removed for MRI - Hair implants that involve staples or metal - Hearing aid(s) that cannot be removed for MRI - Dentures or retainers that cannot be removed for MRI

Study Design


Intervention

Behavioral:
Brain training
Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.
Paced breathing
After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.

Locations

Country Name City State
United States University of Southern California Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of Southern California University of California, Irvine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in plasma pTau-181/tau ratio [ Time Frame: Measured from blood draws at lab visits on Weeks 2, 7, and 12 ] We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction with plasma pTau-181/tau ratio as the dependent variable (to assess group differences in change). Measured from blood draws at lab visits on Weeks 2, 7, and 12
Other Change in urine Ab42 We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction with urine Ab42 as the dependent variable (to assess group differences in change). Measured from urine samples at lab visits on Weeks 2, 7, and 12
Primary Change in plasma amyloid beta levels We will compute an aggregate score based on both plasma Ab40 and Ab42 levels. This score will be compared for Week 2 (pre-intervention), Week 7 (during intervention) and Week 12 (post intervention). We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction in plasma Ab levels (to assess group differences in change). Measured from blood draws at lab visits on Weeks 2, 7, and 12
Primary Change in plasma Ab42/40 ratio [ Time Frame: Measured from blood draws at lab visits on Weeks 2, 7, and 12 ] We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction with plasma Ab42/40 ratio scores as the dependent variable (to assess group differences in change). Measured from blood draws at lab visits on Weeks 2, 7, and 12
Secondary Change in brain perivascular space volume We will test whether there are group differences in change in perivascular space volume Measured from magnetic resonance imaging completed at lab visits on Weeks 2, 7, and 12
Secondary Change in hippocampal volume We will test whether there are group differences in change in hippocampal volume Measured from magnetic resonance imaging completed at lab visits on Weeks 2, 7, and 12
Secondary Brain training performance on 12 Lumosity games during the breathing intervention (controlling for brain training performance pre intervention) We will compute a general learning factor across performance on all 12 games played daily during the intervention period (Weeks 3-11). We will also assess game performance in the pre-intervention Week 2 to provide a baseline performance measure for each participant and statistically account for it. Pre intervention (daily during Week 2) and during intervention (daily during Weeks 3-11)
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A